Evidence map›Paper›PMID 40722078›Full record

ArticleBMC cancer2025

Trends in urinary tract cancer incidence in Golestan province, Iran: a 16-year population-based study.

Behnaz Rahatijafarabad, AmirHoushang Poorkhani, Fatemeh Esfandiari, SeyyedMehdi Sedaghat, Fatemeh Ghasemi-Kebria, Susan Hasanpour-Heidari, Saeid Amirkhanlou, Gholamreza Roshandel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Behnaz RahatijafarabadGolestan Research Center of Gastroenterology and Hepatology, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran.
AmirHoushang PoorkhaniCancer Research Center, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran.
Fatemeh EsfandiariDepartment of Surgery, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
SeyyedMehdi SedaghatDeputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran.
Fatemeh Ghasemi-KebriaGolestan Research Center of Gastroenterology and Hepatology, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran.
Susan Hasanpour-HeidariGolestan Research Center of Gastroenterology and Hepatology, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran.
Saeid AmirkhanlouDepartment of Internal Medicine, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. drsam74ir@ymail.com.
Gholamreza RoshandelGolestan Research Center of Gastroenterology and Hepatology, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran. roshandel_md@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrinary tract cancers (UTC), particularly bladder and kidney cancers, are associated with high mortality rates globally. In Iran, and specifically in Golestan province, an increasing trend in the incidence of these cancers has been reported. This study aims to analyze cancer trends and inform health policy planning to reduce the burden of these diseases in Golestan.

methodsData was collected from the Golestan Population-Based Cancer Registry (GPCR) covering cases of UTC, particularly kidney and bladder cancer from 2004 to 2019. Crude and age-standardized rates (ASR) of kidney and bladder cancers were calculated and presented per 100,000 person-years. Estimated annual percent changes (EAPC) of the ASRs were calculated to investigate time trends in incidence rates.

resultsThe ASR for kidney cancer was 2.32 per 100,000, with rates of 2.75 for men and 1.91 for women. Bladder cancer had an ASR of 5.93, with 9.46 in men and 2.52 in women. Urban populations experienced higher incidence rates as 2.71 for kidney cancer and 7.01 for bladder cancer versus 1.87 and 4.80 in rural areas, respectively. The estimated annual percentage change in incidence was 3.68% for kidney and 1.56% for bladder cancer.

conclusionOur findings suggest high rates and increasing trends in incidence of kidney and bladder cancers in Golestan. The study indicates higher kidney and bladder cancer rates in men and urban residents. Further investigations are warranted to assess the effects of risk factors like smoking, opioid drug use and agricultural factors on incidence of urinary tract cancers in this population.

Indexed as

Kidney NeoplasmsUrinary Bladder NeoplasmsUrologic NeoplasmsAdolescentAdultAgedAged, 80 and overFemaleHumansIncidenceIranMaleMiddle AgedRegistriesRural PopulationUrban PopulationBladderCancerIncidenceKidneyTime Trend

Identifiers

PMID40722078
PMCPMC12305981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.